drugset / Trial / NCT06046742

A Study of Intravenous M1-c6v1 for Locally Advanced or Metastatic Solid Tumors

NCT06046742

Phase 1 Recruiting 12 enrolled Guangzhou Virotech Pharmaceutical Co., Ltd.
NaSingle-groupOpen-labelTreatment

Summary

A Phase I Study of the Safety and Tolerability of M1-c6v1 Administered Via Intravenously for Treatment of Patients With Locally Advanced or Metastatic Solid Tumors

Timeline

Start
2024-07-10
Primary completion
2026-06-30
Completion
2026-12-20

Drugs

EvaluationDrugModalityDoseRoute
Subject M1-c6v1 Unknown Intravenous

Indications